Global /South Korea /Healthcare /Medical Devices /229000

Gencurix Inc.

229000

• KRX: 229000 • Delayed

2,340KRW -1.7%

1.53 USD

As of 13 June 2026, Gencurix Inc. has a market cap of $36.66M USD, ranking #32812 globally and #1967 in South Korea. It ranks #2959 in the Healthcare sector, and #621 in the Medical Devices industry.

Global Rank

32812

Country Rank

1967

Sector Rank

2959

Industry Rank

621

Key Stats

Market Cap

$36.66MUSD

55.76B KRW

Enterprise Value

$38.24MUSD

58.36B KRW

Revenue (TTM)

$2.23MUSD

3.39B KRW

EBITDA (TTM)

-$6.16MUSD

-9.41B KRW

Net Income (TTM)

-$8.25MUSD

-12.55B KRW

EBITDA Margin

-277%

PS Ratio

16.4

PB Ratio

6.6

Company Profile

Country (HQ)

South Korea

Sector

Healthcare

Industry

Medical Devices

CEO

Sung-Rai Cho open_in_new

Founded

2011

Website

gencurix.com open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
-1.7%	3.9%	-11%	31%	56%	53%	32%	-44%	-89%

News

Markets

Exchange	Ticker	Price	Quotes
Korea Exchange (KRX) MIC: XKRX PRIMARY	229000 (주)젠큐릭스 ISIN: KR7229000005 Shares Out.: Shares Outstanding: 23.428M¹ Shares Float: 15.09M² TV: TradingView: KRX: 229000 SA: Stock Analysis: KRX: 229000 YF: Yahoo Finance: 229000.KS GF: Google Finance: KRX: 229000 BA: Barron's: 229000 MS: Morningstar: XKRX: 229000	2,340 KRW	TV: TradingView: KRX: 229000 SA: Stock Analysis: KRX: 229000 YF: Yahoo Finance: 229000.KS GF: Google Finance: KRX: 229000 BA: Barron's: 229000 MS: Morningstar: XKRX: 229000

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About Gencurix Inc.

Gencurix Inc. provides diagnostic solutions in South Korea. Its products include GenesWell BCT, a multigene diagnostic test for breast cancer; Droplex, a genetic test based on digital PCR platform; eDX, an early diagnosis for cancer with liquid biopsy; GenePro SARS-CoV-2 Test kit; GenoCTC, a circulating tumor cell isolator; and GenePro LAMP Cycler, a portable device for infectious disease detection. The company has a strategic alliance with Qiagen N.V. for the development of oncology assays for use on the QIAcuityDx platform. The company was founded in 2011 and is headquartered in Seoul, South Korea.

Similar Companies

Industry: Medical Devices (South Korea)

Name	Market Cap (USD) diff.	PE	Country
CLASSYS Inc. KRX: 214150	$2.47B 3.75T KRW 7K%	28.7	South Korea
SEERS Co., Ltd. KRX: 458870	$1.23B 1.86T KRW 3K%	114.8	South Korea
Livsmed Inc. KRX: 491000	$1.19B 1.81T KRW 3K%	-	South Korea
L&C BIO Co.,LTD KRX: 290650	$1.14B 1.74T KRW 3K%	-	South Korea
Seegene, Inc. KRX: 096530	$759.58M 1.16T KRW 2K%	23.9	South Korea
i3system Inc. KRX: 214430	$532.37M 809.64B KRW 1K%	83.3	South Korea

Industry: Medical Devices (Global)

Name	Market Cap (USD) diff.	PE	Country
Thermo Fisher Scientific Inc. NYSE: TMO	$173.27B 472K%	25.8	United States
Intuitive Surgical, Inc. NASDAQ: ISRG	$160.73B 438K%	56.7	United States
Abbott Laboratories NYSE: ABT	$159.07B 434K%	25.6	United States
Danaher Corp. NYSE: DHR	$126.55B 345K%	34.7	United States
Stryker Corp. NYSE: SYK	$120.69B 329K%	38.3	United States
Medtronic plc NYSE: MDT	$101.9B 278K%	22.2	Ireland

chevron_leftBack